About Proscia
Proscia is a leading healthcare AI company dedicated to transforming pathology through digital solutions, with a primary focus on improving cancer diagnosis and accelerating research. Their flagship offering, the Concentriq® enterprise pathology platform, enables laboratories to transition from traditional microscope-based workflows to a fully digital, data-driven discipline. This platform facilitates the management, analysis, and collaboration on whole slide images, which are massive digital representations of tissue samples. By digitizing pathology, Proscia helps address challenges such as increasing case volumes, staffing shortages, and the need for remote collaboration, ultimately enhancing efficiency, speed, and quality in pathology diagnostics and research.
For physicians, Proscia’s technology provides AI-powered decision support, assisting with well-defined tasks like cancer detection, quantification, and spatial analysis. The platform integrates a precision medicine AI portfolio, which includes applications for biomarker discovery, patient stratification for clinical trials, and diagnostic interpretation tasks. This allows pathologists to work more efficiently and consistently, reducing variability and enabling them to focus on complex interpretations. Proscia’s solutions have received regulatory approvals, including FDA 510(k) clearance and CE-IVDR certification for its diagnostic software, establishing credibility in global markets and supporting the adoption of AI-driven pathology for precision medicine.
The company’s approach is designed to empower both diagnostic laboratories and life sciences organizations. For diagnostic labs, Concentriq streamlines workflows, integrates with existing laboratory information systems (LIS), and supports high-throughput operations. In life sciences, Proscia’s platform and AI offerings are leveraged across drug discovery, translational research, and clinical development to analyze tissue more quantitatively, accelerate the development of novel therapies, and facilitate the creation of AI-based biomarkers.
Focus Areas
Business Intelligence
| Key Investors | Insight Partners, AI Capital Partners (Alpha Intelligence Capital's US fund), Triangle Peak Partners, Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures, Razor's Edge, Scale Venture Partners, Hitachi Ventures, Highline Capital Management, ROBO Global, Flybridge Capital Partners, RobinHood Ventures |
| Partnerships | Agilent Technologies, Siemens Healthineers, Pictor Labs, Primaa, Quest Diagnostics, Ibex Medical Analytics, Aiforia Technologies Plc, Pandclab, Hamamatsu NanoZoomer S360MD (for FDA clearance), Johns Hopkins, University of Pittsburgh Medical Center (UPMC) |
| Technology | Concentriq® enterprise pathology platform (cloud-native, open platform, AI operating system, REST APIs, events, data warehouse, foundation model integrator, Concentriq Embeddings) |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Proscia's platform offers several key advantages. It enhances diagnostic accuracy and consistency through AI-powered image analysis and biomarker quantification, reducing subjective variability. The ability to access and review cases remotely, combined with seamless consultation capabilities, significantly improves workflow efficiency and turnaround times. By automating routine tasks, AI frees up pathologists to focus on complex interpretations, thereby increasing their impact on patient care. Furthermore, the platform's integration with existing LIS/EHR systems and its scanner-agnostic approach ensure a smooth transition to digital pathology without disrupting established workflows. Ultimately, Proscia empowers pathologists with advanced insights from AI-driven biomarkers and real-world data, enabling more precise diagnoses and supporting targeted treatment decisions in the era of precision medicine.
Proscia's Concentriq platform is built as an open and interoperable ecosystem, crucial for modern pathology labs. It is scanner-agnostic, supporting various manufacturers and DICOM standards. The platform offers deep, bidirectional integration with leading Laboratory Information Systems (LIS) and Electronic Health Records (EHR) systems, including Epic Beaker, to ensure seamless data synchronization and preserve existing clinical workflows. Proscia actively partners with a broad range of third-party AI application developers (e.g., Visiopharm, Nucleai, Mindpeak) and other technology providers (e.g., Smart Reporting, Siemens Healthineers, Pramana) through its 'Proscia Ready' alliance, allowing laboratories to integrate best-of-breed solutions and avoid vendor lock-in. This open architecture ensures flexibility and future-readiness for evolving digital pathology needs.
What the Web Says
Proscia is a software company focused on accelerating the transition to digital pathology and enabling AI in precision medicine. Their Concentriq enterprise pathology platform and AI portfolio are used by pharmaceutical companies and diagnostic laboratories. The company has received FDA 510(k) clearance and CE-IVDR certification for its diagnostic software. Proscia's Concentriq platform has been recognized as a top-performing digital pathology platform in both the US and Europe by KLAS Research in 2026, with customers reporting high satisfaction and long-term commitment to the platform.
Overall: MixedStrengths
- Concentriq platform is highly rated for overall performance and customer satisfaction.
- Platform is scanner-agnostic and integrates with various imaging hardware, LIS, and third-party AI applications.
- Enables more efficient workflows, faster diagnoses, and improved collaboration.
- Supports large image files, loading them quickly even at an enterprise scale.
- Mission-driven company focused on quality and precise results.
- Strong customer support and commitment to project success.
Limitations
- Some employee reviews mention a toxic company culture and lack of support/training.
- Concerns raised on Reddit about the company's push for AI potentially replacing pathologists and the safety of their offerings.
- One Reddit user expressed a preference for a competitor's image viewer and LIS system.
- Initial setup of the software can be time-consuming.
- One review mentioned that the search function in the software could be improved.
Based on reviews from: Indeed.com, FeaturedCustomers, Insight Partners, Reddit, Proscia.com, Comparably, G2.com, Capterra, KLAS Research
Last updated: 2026-08-13
Videos
News, demos, and interviews about Proscia.
Videos load interactively. If none appear, search YouTube for Proscia →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Proscia.
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]